You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明巨諾-B(02126.HK)在第63屆美國血液學會年會上公佈倍諾達®主要臨牀效果
格隆匯 12-13 08:12

格隆匯12月13日丨藥明巨諾-B(02126.HK)今日在第63屆美國血液學會年會上公佈了倍諾®(瑞基奧侖賽注射液)用於治療復發╱難治性(r/r)濾泡淋巴瘤(FL)中國成人患者中的主要臨牀效果。

到數據截至日2021年9月10日,共有28例復發╱難治性濾泡淋巴瘤中國成人患者接受了倍諾達®的治療,並達到了至少三個月的隨訪期。在27例可評估有效性的患者中,基於研究者評估的最佳客觀緩解率(“ORR)為100% (27/27),最佳完全緩解率("CRR)為92.6%(25/27)。中位隨訪時間8.84個月,未達到中位緩解持續時間(“DOR)、中位無進展生存期("PFS)及中位總生存期(“OS)。在接受倍諾達®治療的28例患者中,所有級別及重度(≥3級)細胞因子釋放綜合徵(“CRS)的發生率分別為42.9%及0%,所有級別及重度(≥3級)神經毒性(“NT)的發生率分別為17.9%及3.6%。

藥明巨諾首席醫學官Mark J. Gilbert博士表示:"多數復發難治性濾泡性淋巴瘤患者無法治癒、最終無法避免疾病復發或進展。倍諾達®的這項關鍵性臨牀研究,證實了它在復發難治性濾泡性淋巴瘤患者中可實現較高的腫瘤緩解率及可控的毒副反應。我們深受這些臨牀資料的鼓舞,並期待儘早將倍諾達®的適應症拓展到復發難治性濾泡性淋巴瘤,以期造福更多患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account